Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
Microbix Biosystms ( (TSE:MBX) ) has provided an announcement.
Microbix Biosystems Inc. has announced a collaboration with the American Proficiency Institute (API) to launch a pilot proficiency testing program aimed at validating the accuracy of molecular assays in detecting the H5N1 strain of the Influenza A virus. This initiative addresses a critical need to ensure that diagnostic tests can reliably identify this potentially pandemic-causing strain, enhancing health systems’ responsiveness. Microbix has developed a novel quality assessment product that includes the whole genome of the H5N1 virus without containing infectious materials, allowing clinical labs to independently verify their diagnostic assays through API’s testing program.
More about Microbix Biosystms
Microbix Biosystems Inc. is a life sciences company involved in innovation, manufacturing, and exporting within the biotechnology sector. The company focuses on creating quality assessment products for diagnostic testing, leveraging its expertise in virology and synthetic biology.
YTD Price Performance: 5.00%
Average Trading Volume: 116,127
Technical Sentiment Consensus Rating: Sell
Current Market Cap: C$56.48M
For a thorough assessment of MBX stock, go to TipRanks’ Stock Analysis page.
